Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCEH1 | Q6PIU2 | 4/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8705200 | 0.80 | MTNR1A (0.58) | MTNR1AMTNR1BSLC2A1 | |
| SCHEMBL8873933 | 0.80 | MTNR1A (0.58) | MTNR1AMTNR1BSLC2A1 | |
| SCHEMBL6077487 | 0.79 | MTNR1A (0.43) | MTNR1AMTNR1BSLC2A1 | |
| SCHEMBL6077494 | 0.74 | MTNR1A (0.42) | MTNR1AMTNR1BSLC2A1 | |
| SCHEMBL5344998 | 0.72 | MTNR1A (0.50) | MTNR1AMTNR1BALDH1A1KMT2A | |
| SCHEMBL7848652 | 0.71 | MTNR1A (0.43) | MTNR1AMTNR1BSLC2A1 | |
| SCHEMBL5351881 | 0.71 | MTNR1A (0.49) | MTNR1AMTNR1B | |
| SCHEMBL6076454 | 0.71 | MTNR1A (0.49) | MTNR1AMTNR1BSLC2A1 | |
| SCHEMBL5343898 | 0.71 | MTNR1A (0.49) | MTNR1AMTNR1B | |
| SCHEMBL6075796 | 0.68 | MTNR1A (0.47) | MTNR1AMTNR1BSLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7126012-B2 | Substituted cyclic compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-24 | — | — | US | disclosed |
| US-7115752-B2 | Substituted cyclic compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-03 | — | — | US | disclosed |
| US-20050124682-A1 | Substituted cyclic compounds | LESIEUR DANIEL (FR) | 2005-06-09 | — | — | US | disclosed |
| US-6872851-B1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATORIES SERVIER (FR) | 2005-03-29 | — | — | US | disclosed |
| US-20050059729-A1 | Substituted cyclic compounds | LESIEUR DANIEL (FR) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059729-A1 | Substituted cyclic compounds | CCNY, CCNT2, TECR | NCEH1 3796/4885MTNR1A 465/4885MTNR1B 414/4885 |
| US-20050124682-A1 | Substituted cyclic compounds | CCNY, CCNT2, TECR | NCEH1 3796/4885MTNR1A 465/4885MTNR1B 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.